Activation of the Akt and NF-κB signaling pathways may lead to temozolomide resistance in GBM by inhibiting TNF-alpha-induced protein 3 (TNFAIP3), as suggested by Chen et al. 2022b. This evidence concerns the gene NFKB1 and glioblastoma.